Recent progress in pharmacological and non-pharmacological treatment options of major depression

Current Pharmaceutical Design

Volumn 12, Issue 4, 2006, Pages 503-515

  Baghai, Thomas C ^a   Möller, Hans Jürgen ^a   Rupprecht, Rainer ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Antidepressants; Clinical trials; Cortisol; Depression; Electroconvulsive therapy; Tachykinin

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 (2 CHLORO 4 METHOXY 5 METHYLPHENYL) N [2 CYCLOPROPYL 1 (3 FLUORO 4 METHYLPHENYL)ETHYL] 5 METHYL N (2 PROPYNYL) 2 THIAZOLAMINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; AGOMELATINE; ANTIDEPRESSANT AGENT; APREPITANT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; C 1073; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; GEPIRONE; GLUCOCORTICOID RECEPTOR ANTAGONIST; HYDROCORTISONE; IMIPRAMINE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PRASTERONE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ADRENAL INSUFFICIENCY; BODY WEIGHT DISORDER; CLINICAL TRIAL; DECREASED APPETITE; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ELECTROCONVULSIVE THERAPY; FATIGUE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LATENT PERIOD; MAGNETIC SEIZURE THERAPY; MAGNETOTHERAPY; MAJOR DEPRESSION; NAUSEA; NONHUMAN; NORADRENERGIC SYSTEM; PHOTOTHERAPY; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SLEEP DEPRIVATION; SOCIOECONOMICS; TACHYCARDIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE; TREMOR; VAGUS NERVE STIMULATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BIOLOGICAL MODEL; ELECTROSTIMULATION THERAPY; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; VAGUS NERVE;

ANIMALS; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; ELECTRIC STIMULATION THERAPY; HUMANS; MODELS, BIOLOGICAL; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE;

EID: 33644881111     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775474422     Document Type: Review

References (144)

1. Burke MJ, Preskorn SH. Short term treatment of mood disorders with standard antidepressants. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press 1995; 1053-1065.
2. Stahl SM. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. J Clin Psychiatry 1998; 59: 23-29.
3. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
4. Frodl T, Meisenzahl E, Zetzsche T, Born C, Groll C, Jager M, et al. Hippocampal changes in patients with first episode of major depression. Am J Psychiatry 2002; 159: 1112-1118.
5. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
6. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355(9207): 911-918.
7. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001; 62(12): 16-23.
8. Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001; 21(21): 8319-8323.
9. Pacher P, Kohegyi E, Kecskemeti V, Furst S. Current trends in the development of new antidepressants. Curr Med Chem 2001; 8(2): 89-100.
10. Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999; 14(6): 329-337.
11. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61(9): 656-663.
12. Montgomery SA. New developments in the treatment of depression. J Clin Psychiatry 1999; 60(Suppl 14): 10-15.
13. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 1996, 30(6): 441-451.
14. Wu JC, Bunney, W.E. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990; 147: 14-21.
15. ECT review group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361(9360): 799-808.
16. Gangadhar BN, Kapur RL, Kalyanasundaram S. Comparison of electroconvulsive therapy with imipramine in endogenous depression: a double blind study. Br J Psychiatry 1982; 141: 367-371.
17. Charney DS, Grothe DR, Smith SL, Brady KT, Kaltsounis-Puckett J, Wright CW, et al. Overview of psychiatric disorders and the role of newer antidepressants. J Clin Psychiatry 2002; 63: 3-9.
18. Rush AJ, Thase ME, Dube S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003; 53(8): 743-753.
19. Grote NK, Frank E. Difficult-to-treat depression: the role of contexts and comorbidities. Biol Psychiatry 2003; 53(8): 660-670.
20. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18(6): 444-455.
21. Moller HJ. Anxiety associated with comorbid depression. J Clin Psychiatry 2002; 63(Suppl 14): 22-26.
22. Laakmann G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T. Are benzodiazepines antidepressants? Psychopharmacology (Berl) 1996; 124(3): 291-292.
23. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001; 15(10): 797-817.
24. Dinan TG, Lavelle E, Cooney J, Burnett F, Scott L, Dash A, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand 1997; 95(1): 58-61.
25. Arana GW, Santos AB, Laraia MT, McLeod-Bryant S, Beale MD, Rames LJ, et al. Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995; 152(2): 265-267.
26. Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978; 35(5): 639-642.
27. Folkerts HW, Michael N, Tolle R, Schonauer K, Mucke S, Schulze-Monking H. Electroconvulsive therapy vs. paroxetine in treatment-resistant depression - a randomized study. Acta Psychiatr Scand 1997; 96(5): 334-342.
28. Kroessler D. Relative Efficacy Rates for Therapies of Delusional Depression. Convuls Ther 1985; 1(3): 173-182.
29. Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry 1997; 54(11): 1009-1015.
30. Lesieur D, Leclerc V, Chavatte P, Marcot C, Renard P, Guardiola-Lemaitre B. Melatonin: a pertinent prototype for therapeutic intervention. Therapie 1998; 53: 429-437.
31. Foulkes NS, Borjigin J, Snyder SH, Sassone-Corsi P. Rhythmic transcription: the molecular basis of circadian melatonin synthesis. Trends Neurosci 1997; 20: 487-492.
32. Tuma S, Strubbe JJ, Mocaer E, Koolhaas JM. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delay of circadian rhythms of the rat. Chronobiol Int 2002; 18: 781-799.
33. Van Reeth O, Olivares E, Zhang Y, Tripathi B, Turek FW. Chronobiotic effects of gepirone, a potential antidepressant with 5HT1A receptor partial agonist properties. Behav Pharmacol 1999; 10(2): 119-130.
34. Silva RC, Brandao ML. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis. Pharmacol Biochem Behav 2000; 65(2): 209-216.
35. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996; 32(3): 335-342.
36. Feiger AD. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 1996; 32(4): 659-665.
37. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64(3): 243-249.
38. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64(3): 243-249.
39. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281: 1640-1645.
40. Stout SC, Owens MJ, Nemeroff CB. Neurokinin(1) receptor antagonists as potential antidepressants. Annu Rev Pharmacol Toxicol 2001; 41: 877-906.
41. Morcuende S, Gadd CA, Peters M, Moss A, Harris EA, Sheasby A, et al. Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur J Neurosci 2003; 18(7): 1828-1836.
42. Rupniak NM. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr Opin Investig Drugs 2002; 3(2): 257-261.
43. Bondy B, Baghai TC, Minov C, Schule C, Schwarz MJ, Zwanzger P, et al. Substance P serum levels are increased in major depression: preliminary results. Biol Psychiatry 2003; 53(6): 538-542.
44. Baghai TC, Schule C, Zwanzger P, Minov C, Schwarz MJ, de Jonge S, et al. Possible influence of the insertion/deletion polymorphisms in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders. Mol Psychiatry 2001; 6: 258-259.
45. Baghai TC, Schule C, Zwanzger P, Minov C, Zill P, Ella R, et al. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphisms of the angiotensin I-converting enzyme gene. Neurosci Lett 2002; 328: 299-303.
46. Kramer MS. Clinical update: substance P antagonists in patients with major depression. Eur Psychiatry 2002; 17(1): 10.
47. Holsboer F. Antidepressant drug discovery in the postgenomic era. World J Biol Psychiatry 2001; 2: 165-177.
48. Holsboer F, Spengler D, Heuser IJ. The role of corticotropin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 1992; 93: 385-417.
49. Nemeroff CB, Widerlöv E, Bisette G, Walleus H, Karlsson I, Eklund K, et al. Elevated concentrations of CSF corticotropin-releasingfactor- like immunoreactivity in depressed patients. Science 1984; 226: 1342-1343.
50. Linkowski P, Mendlewicz J, Kerkhofs M, Leclerq R, Goldstein J, Brasseur M, et al. 24-hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: effect of antidepressant treatment. J Clin Endocrinol Metab 1987; 65: 141-152.
51. Arana GW, Baldessarini RJ, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch Gen Psychiatry 1985; 42: 1193-1204.
52. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140: 292-304.
53. Holsboer F, v.Bardeleben U, Gerken A, Stalla GK, Müller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med 1984; 311: 1127.
54. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. N Engl J Med 1986; 314: 1329-1335.
55. Amsterdam JD, Winokur A, Abelmann E, Lucki I, Rickels K. Cosyntropin (ACTH1-24) stimulation test in depressed patients and healthy subjects. Am J Psychiatry 1984; 140: 907-909.
56. von Bardeleben U, Holsboer F. Cortisol response to a combined dexamethasone-hCRH chellenge in patients with depression. J Neuroendocrinol 1989; 1: 485-488.
57. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 1994; 28(4): 341-356.
58. Hatzinger M, Hemmeter UM, Baumann K, Brand S, Holsboer-Trachsler E. The combined DEX-CRH test in treatment course and long-term outcome of major depression. J Psychiatr Res 2002; 36(5): 287-297.
59. Zobel AW, Yassouridis A, Frieboes R-M, Holsboer F. Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 1999; 156: 949-951.
60. Barden N, Reul JMHM, Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1995; 18(1): 6-11.
61. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 1996; 17(2): 187-205.
62. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. J Clin Invest 1991; 87: 831-837.
63. Reul JMHM, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary- adrenocortical system. Endocrinology 1993; 133: 312-320.
64. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F, et al. The anxiolytic effects of the CRH(1) receptor antagonist depends on innate emotionality in rats. Eur J Neurosci 2001; 13: 373-380.
65. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P, et al. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl- 1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 2002; 301(1): 333-345.
66. Arborelius L, Skelton KH, Thrivikraman KV, Plotsky PM, Schulz DW, Owens MJ. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 2000; 294(2): 588-597.
67. Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Nakazato A, et al. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J Pharmacol Exp The 1999; 289(2): 926-935.
68. Zobel AW, Nickel T, Künzel HE, Ackl N, Sonntag A, Ising M, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000; 34: 171-181.
69. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, et al. Limited efficacy of ketoconazole in treatment-refractory major depression. J Clin Psychopharmacol 1999; 19(5): 466-470.
70. Murphy BEP. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Molec Biol 1991; 39: 239-244.
71. Wolkowitz OM, Reus VI, Manfredi F, Ingbar J, Brizendine L, Weingartner H. Ketoconazole administration in hypercortisolemic depression. Am J Psychiatry 1993, 150: 810-812.
72. Anand A, Malison RT, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biol Psychiatry 1995; 37: 338-340.
73. Thakore JH, Dinan TG. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37: 364-368.
74. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995; 37: 369-375.
75. Sovner R, Fogelman S. Ketoconazole therapy for atypical depression. J Clin Psychiatry 2002; 57: 227-228.
76. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson P, et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biol Psychiatry 1999; 45: 1070-1074.
77. Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE. Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmcol 1999; 145: 303-308.
78. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991; 11: 121-126.
79. Raven PW, O'Dwyer A-M, Taylor NF, Checkley SA. The relationship between the effects of metyrapone treatment on depressed mood and urinary steroid profiles. Psychoneuroendocrinol 1996; 21(3): 277-286.
80. O'Dwyer A-M, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995; 33: 123-128.
81. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22(9): 410-416.
82. A receptor. Brain Res 1991; 561: 157-161.
83. Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3 α-hydroxy-5α-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 2000; 67(1): 137-143.
84. Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J Psychiatr Res 1997; 31: 297-314.
85. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156(4): 646-649.
86. Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996; 81: 3147-3151.
87. Flood JF, Smith GE, Roberts E. Dehydroepiandrosterone and its sulfate enhance memory retention in mice. Brain Res 1988; 447: 269-278.
88. 1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298(3): 1269-1279.
89. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997; 41: 311-318.
90. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab 1998; 83(9): 3130-3133.
91. Murphy BEP, Filipini D, Ghadirian AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 1993; 18: 209-213.
92. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002; 52(5): 386-392.
93. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001; 21(5): 516-521.
94. Greenblatt M, Grosser GH, Wechsler HA. Differential response of hospitalized depressed patients in somatic therapy. Am J Psychiatry 1964; (120): 935-943.
95. Janicak PG, Davis JM, Gibbons RD, Ericksen S, Chang S, Gallagher P. Efficacy of ECT: a meta-analysis. Am J Psychiatry 1985; 142(3): 297-302.
96. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry 1996; 153(8): 985-992.
97. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody BJ, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med 1993; 328(12): 839-846.
98. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res 1990: 31(3): 287-296.
99. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser S, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry 2000; 57(5): 425-434.
100. Sackeim HA, Decina P, Kanzler M, Kerr B, Malitz S. Effects of electrode placement on the efficacy of titrated, low-dose ECT. Am J Psychiatry 1987; 144(11): 1449-1455.
101. van Waarde JA, Stek ML. Electroconvulsive therapy effective and safe in 55 patients aged 56 years and older with mood disorders and physical comorbidity. Ned Tijdschr Geneeskd 2001; 145(35): 1693-1697.
102. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. Arch Gen Psychiatry 2000; 57(6): 581-590.
103. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry 1990; 147(1): 14-21.
104. Schilgen B, Tolle R. Partial sleep deprivation as therapy for depression. Arch Gen Psychiatry 1980; 37(3): 267-271.
105. Ringel BL, Szuba MP. Potential mechanisms of the sleep therapies for depression. Depress Anxiety 2001; 14(1): 29-36.
106. Holsboer-Trachsler E, Seifritz E. Sleep in depression and sleep deprivation: a brief conceptual review. World J Biol Psychiatry 2000; 1(4): 180-186.
107. Schule C, Baghai T, Zwanzger P, Minov C, Padberg F, Rupprecht R. Sleep deprivation and hypothalamic-pituitary-adrenal (HPA) axis activity in depressed patients. J Psychiatr Res 2001; 35(4): 239-247.
108. Benedetti F, Barbini B, Campori E, Colombo C, Smeraldi E. Dopamine agonist amineptine prevents the antidepressant effect of sleep deprivation. Psychiatry Res 1996; 65(3): 179-184.
109. Ebert D, Feistel H, Kaschka W, Barocka A, Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 1994; 35(11): 880-885.
110. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, di Bella D, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156(9): 1450-1452.
111. Grube M, Hartwich P. Maintenance of antidepressant effect of sleep deprivation with the help of lithium. Eur Arch Psychiatry Clin Neurosci 1990; 240(1): 60-61.
112. Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol 1999; 19(3): 240-245.
113. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology 1999; 20(4): 380-385.
114. Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res 2000; 95(1): 43-53.
115. Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatry 1996; 39(1): 16-21.
116. Kuhs H, Kemper B, Lippe-Neubauer U, Meyer-Dunker J, Tolle R. Repeated sleep deprivation once versus twice a week in combination with amitriptyline. J Affect Disord 1998; 47(1-3): 97-103.
117. Kuhs H, Farber D, Borgstadt S, Mrosek S, Tolle R. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord 1996; 37(1): 31-41.
118. Berger M, Vollmann J, Hohagen F, Konig A, Lohner H, Voderholzer U, et al. Sleep deprivation combined with consecutive sleep phase advance as a fast-acting therapy in depression: an open pilot trial in medicated and unmedicated patients. Am J Psychiatry 1997; 154(6): 870-872.
119. Voderholzer U, Valerius G, Schaerer L, Riemann D, Giedke H, Schwarzler F, et al. Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study. Eur Arch Psychiatry Clin Neurosci 2003; 253(2): 68-72.
120. Lee TM, Chan CC. Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiatr Scand 1999; 99(5): 315-323.
121. Rosenthal NE, Sack DA, Carpenter CJ, Parry BL, Mendelson WB, Wehr TA. Antidepressant effects of light in seasonal affective disorder. Am J Psychiatry 1985; 142(2): 163-170.
122. Compton MT, Nemeroff CB. The treatment of bipolar depression. J Clin Psychiatry 2000; 61 (Suppl 9): 57-67.
123. Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Morning sunlight reduces length of hospitalization in bipolar depression. J Affect Disord 2001; 62(3): 221-223.
124. Prasko J, Horacek J, Klaschka J, Kosova J, Ondrackova I, Sipek J. Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. Neuroendocrinol Lett 2002; 23(2): 109-113.
125. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry 2003; 64(6): 648-653.
126. Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy. Depress Anxiety 2002; 16(1): 1-3.
127. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3(1): 5-43.
128. Conca A, Koppi S, Konig P, Swoboda E, Krecke N. Transcranial magnetic stimulation: a novel antidepressive strategy? Neuropsychobiology 1996; 34(4): 204-207.
129. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry 2003; 160(5): 835-845.
130. Berman RM, Narasimhan M, Sanacora G, Miano AP, Hoffman RE, Hu XS, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. Biol Psychiatry 2000; 47(4): 332-337.
131. George MS, Nahas Z, Molloy M, Speer AM, Oliver NC, Li XB, et al. A controlled trial of daily left prefrontal cortex TMS for treating depression. Biol Psychiatry 2000; 48(10): 962-970.
132. Padberg F, Zwanzger P, Keck ME, Kathmann N, Mikhaiel P, Ella R, et al. Repetitive transcranial magnetic stimulation (rTMS) in major depression: relation between efficacy and stimulation intensity. Neuropsychopharmacology 2002; 27(4): 638-645.
133. Padberg F, Zwanzger P, Thoma H, Kathmann N, Haag C, Greenberg BD, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res 1999; 88(3): 163-171.
134. Grunhaus L, Dannon PN, Schreiber S, Dolberg OH, Amiaz R, Ziv R, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study. Biol Psychiatry 2000; 47(4): 314-324.
135. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. Biol Psychiatry 2003; 53(4): 324-331.
136. Padberg F, Moller HJ. Repetitive transcranial magnetic stimulation: does it have potential in the treatment of depression? CNS Drugs 2003; 7(6): 383-403.
137. Lisanby SH. Update on magnetic seizure therapy: a novel form of convulsive therapy. J ECT 2002, 18(4): 182-188.
138. Lisanby SH, Schlaepfer TE, Fisch HU, Sackeim HA. Magnetic seizure therapy of major depression. Arch Gen Psychiatry 2001; 58(3): 303-305.
139. Kosel M, Frick C, Lisanby SH, Fisch HU, Schlaepfer TE. Magnetic Seizure Therapy Improves Mood in Refractory Major Depression. Neuropsychopharmacology 2003; 28(1): 2045-8.
140. Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and Feasibility of Magnetic Seizure Therapy (MST) in Major Depression: Randomized Within-Subject Comparison with Electroconvulsive Therapy. Neuropsychopharmacology 2003; 28(10): 1852-1865.
141. Goodnick PJ, Rush AJ, George MS, Marangell LB, Sackeim HA. Vagus nerve stimulation in depression. Expert Opin Pharmacother 2001; 2(7): 1061-1063.
142. Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology 2001; 25(5): 713-728.
143. Carpenter LL, Friehs GM, Price LH. Cervical vagus nerve stimulation for treatment-resistant depression. Neurosurg Clin N Am 2003; 14(2): 275-282.
144. Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, et al. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003; 64(3): 243-249.